Apparent Diffusion Coefficient as a Predictive Biomarker for Survival in Patients with Treatment-Naive Glioblastoma Using Quantitative Multiparametric Magnetic Resonance Profiling.
暂无分享,去创建一个
Byung Sup Kim | H. Seol | Jung-Il Lee | S. Kim | D. Kong | D. Nam | H. Shin | Joon-Hyung Kim
[1] In-Hee Lee,et al. Quantitative radiomic profiling of glioblastoma represents transcriptomic expression , 2018, Oncotarget.
[2] Chaofeng Liang,et al. A Fully-Automatic Multiparametric Radiomics Model: Towards Reproducible and Prognostic Imaging Signature for Prediction of Overall Survival in Glioblastoma Multiforme , 2017, Scientific Reports.
[3] M. Barış,et al. Role of mass effect, tumor volume and peritumoral edema volume in the differential diagnosis of primary brain tumor and metastasis , 2016, Clinical Neurology and Neurosurgery.
[4] Dong Wook Kim,et al. Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma. , 2016, Radiology.
[5] T. Dwight,et al. Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma , 2016, Scientific Reports.
[6] Paul Kinahan,et al. Radiomics: Images Are More than Pictures, They Are Data , 2015, Radiology.
[7] D. O’Rourke,et al. Prognostic Value of Dynamic Susceptibility Contrast-Enhanced and Diffusion-Weighted MR Imaging in Patients with Glioblastomas , 2015, American Journal of Neuroradiology.
[8] W. Pope. Genomics of brain tumor imaging. , 2015, Neuroimaging clinics of North America.
[9] Susan M. Chang,et al. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab , 2014, Journal of Neuro-Oncology.
[10] Maciej A. Mazurowski,et al. Computer-extracted MR imaging features are associated with survival in glioblastoma patients , 2014, Journal of Neuro-Oncology.
[11] H. Fathallah-Shaykh,et al. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters , 2014, Journal of Neuro-Oncology.
[12] G. Reifenberger,et al. MGMT testing—the challenges for biomarker-based glioma treatment , 2014, Nature Reviews Neurology.
[13] Luke Macyszyn,et al. Pattern analysis of dynamic susceptibility contrast-enhanced MR imaging demonstrates peritumoral tissue heterogeneity. , 2014, Radiology.
[14] P. Lambin,et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.
[15] A. Lagares,et al. A Prognostic Model Based on Preoperative MRI Predicts Overall Survival in Patients with Diffuse Gliomas , 2014, American Journal of Neuroradiology.
[16] Christopher P. Hess,et al. Susceptibility-weighted MR imaging of radiation therapy-induced cerebral microbleeds in patients with glioma: a comparison between 3T and 7T , 2014, Neuroradiology.
[17] R. Gillies,et al. Quantitative imaging in cancer evolution and ecology. , 2013, Radiology.
[18] Jordan M. Malof,et al. Imaging descriptors improve the predictive power of survival models for glioblastoma patients. , 2013, Neuro-oncology.
[19] G. Reifenberger,et al. Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations , 2013, Clinical Cancer Research.
[20] William D. Dunn,et al. MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. , 2013, Radiology.
[21] D. Yousem,et al. ADC values and prognosis of malignant astrocytomas: does lower ADC predict a worse prognosis independent of grade of tumor?--a meta-analysis. , 2013, AJR. American journal of roentgenology.
[22] A. Bozzao,et al. Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status , 2013, European Radiology.
[23] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[24] Andre Dekker,et al. Radiomics: the process and the challenges. , 2012, Magnetic resonance imaging.
[25] Christos Davatzikos,et al. GLISTR: Glioma Image Segmentation and Registration , 2012, IEEE Transactions on Medical Imaging.
[26] T. Cloughesy,et al. Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma , 2012, American Journal of Neuroradiology.
[27] M S Brown,et al. Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma , 2011, American Journal of Neuroradiology.
[28] T. Mikkelsen,et al. Predicting survival in glioblastomas using diffusion tensor imaging metrics , 2010, Journal of magnetic resonance imaging : JMRI.
[29] S. Leenstra,et al. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide , 2010, British Journal of Cancer.
[30] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[31] T. Hirai,et al. Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. , 2007, Radiology.
[32] Toshihiro Kumabe,et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. , 2006, Radiology.
[33] Daniel P Barboriak,et al. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. , 2006, Radiology.
[34] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[35] J. Herman,et al. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer , 2004, Oncogene.
[36] R. Bammer. Basic principles of diffusion-weighted imaging. , 2003, European journal of radiology.
[37] Usha Sinha,et al. Relationships Between Choline Magnetic Resonance Spectroscopy, Apparent Diffusion Coefficient and Quantitative Histopathology in Human Glioma , 2000, Journal of Neuro-Oncology.
[38] Scar,et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.
[39] Toshinori Hirai,et al. Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.
[40] S. Plevritis,et al. Glioblastoma Multiforme: Exploratory Radiogenomic Analysis by Using Quantitative Image Features. , 2015, Radiology.
[41] Jill S. Barnholtz-Sloan,et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012 , 2015, Neuro-oncology.
[42] Benjamin M. Ellingson,et al. Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics , 2014, Current Neurology and Neuroscience Reports.
[43] G. Reifenberger,et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.